Other languages Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
3.42 ^USD	+2.40%		+12.87%	+23.47%

Mar. 28	Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	MT
Mar. 28	Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	Mar. 04
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	Jan. 30
Sector Update: Health Care Stocks Advance Late Afternoon	Jan. 22
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type	Jan. 22
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient	Jan. 22
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	Jan. 16
Cellectar Biosciences Partners with MiBA to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting	Jan. 11
Cellectar's blood cancer therapy succeeds in late-stage study	Jan. 08
Cellectar's blood cancer therapy succeeds in trial	Jan. 08
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia	Jan. 08
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation	Dec. 19
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Cellectar Biosciences, Inc. to Release Top-Line Data from Wm Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024	Nov. 02
Cellectar Biosciences, Florida Cancer Specialists & Research Institute to Collaborate on Lymphoma Research	23-10-25
Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines Designation for Iopofosine for Waldenstrom's Macroglobulinemia	23-09-18
Sector Update: Health Care Stocks Falling Late Afternoon	23-09-05
Sector Update: Health Care	23-09-05
Cellectar Biosciences Shares Jump on $102.9 Million Private Placement Financing	23-09-05
Top Midday Gainers	23-09-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Other languages

Filters